ACE Reports.
Make a selection below to explore our full database of 6 results on the topic: "C Libanati"
ACE Reports
(6 Reports)ACE Reports
(6 Reports)
General Orthopaedics
Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543
Metabolic Disorders
WCO-IOF 2016: Greater BMD increase after 1 year of romosozumab vesus teripratide
Metabolic Disorders
Denosumab is superior to alendronate for improving cortical bone porosity post-menopause
Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.
Metabolic Disorders
WCO-IOF: Changes with QCT, DXA, and TBS between denosumab, alendronate, & placebo
Metabolic Disorders
FREEDOM RCT follow-up: Denosumab does not delay fracture healing in osteoporosis patients
J Bone Joint Surg Am. 2012 Oct 24. doi: 10.2106/JBJS.K.00774
General Orthopaedics
Denosumab reduces risk of fractures in post-menopausal women
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.